ZNF503 reduces chemotherapy sensitivity in prostate cancer by activating ISL1 and Notch1 signaling
Cellular Signalling · 2026-09 · 145 · 112602
DOI: 10.1016/j.cellsig.2026.112602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026-09. Verfasst von Yong Nie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Dong Street No. 134, 350001 Fuzhou City, Fujian Province, China…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Signal Transduction, Receptor, Notch1, Transcription Factors. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Fujian Medical University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Prostate cancer (PCa) remains a leading cause of cancer-related mortality, with reduced sensitivity to chemotherapy significantly compromising treatment efficacy. The zinc finger protein 503 (ZNF503) has recently emerged as a potential regulator of cancer progression, but its role in prostate cancer and chemotherapy resistance has yet to be fully elucidated. In this study, we investigate the functional role of ZNF503 in prostate cancer and its involvement in mediating chemotherapy resistance. Using a combination of RNA sequencing, functional assays, and in vivo models, we demonstrate that ZNF503 expression is elevated in chemotherapy-resistant prostate cancer cells and tissues. ZNF503 overexpression enhances tumor cell proliferation, migration, and protects cells from chemotherapy -induced apoptosis following acute exposure to agents such as docetaxel and cisplatin. Mechanistically, we show that ZNF503 activates the Notch1 signaling pathway, a key driver of aggressive cancer phenotypes, and this effect is associated with increased expression of the transcription factor ISL1. Further analysis revealed that ISL1 is required for ZNF503-induced Notch1 activation. Knockdown of ISL1 significantly attenuates ZNF503-induced Notch1 expression and restores chemotherapy sensitivity, underscoring the critical role of the ZNF503-ISL1-Notch1 axis in prostate cancer progression and drug resistance. In clinical samples, high ZNF503 expression correlates with poor prognosis and reduced chemotherapy sensitivity, suggesting that ZNF503 is a candidate prognostic marker that requires further validation in larger, independent cohorts with multivariate analysis. Our findings provide novel insights into the molecular mechanisms underpinning chemotherapy resistance in prostate cancer and position ZNF503 as a promising therapeutic target to overcome drug resistance and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Dong Street No. 134, 350001 Fuzhou City, Fujian Province, China; Department of Urology, Shenzhen Pingle Orthopedic Hospital (Shenzhen…
- Department of Pharmacy, Shenzhen Wang-Chen Traditional Chinese Medicine Hospital, Kejiyuan Road No. 9-15, Longgang District, 518172 Shenzhen City, Guangdong Province, China.
- Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Dong Street No. 134, 350001 Fuzhou City, Fujian Province, China.
- Department of Pathology, Shenzhen Pingle Orthopedic Hospital (Shenzhen Pingshan Traditional Chinese Medicine Hospital), Pingle Road No. 9, Pingshan District, 518118 Shenzhen City, Guangdong Province, China.
- Department of Urology, Shengli Clinical Medical College of Fujian Medical University, Dong Street No. 134, 350001 Fuzhou City, Fujian Province, China. Electronic address: yeliefu2025@163.com.
Förderung
- Fujian Medical University
Zitieren
APA
Nie, Y., Fu, L., Zeng, X., Peng, X., Zhu, Q., Li, Q., & Ye, L. (2026). ZNF503 reduces chemotherapy sensitivity in prostate cancer by activating ISL1 and Notch1 signaling. Cellular Signalling, 145, 112602. https://doi.org/10.1016/j.cellsig.2026.112602
Vancouver
Nie Y, Fu L, Zeng X, Peng X, Zhu Q, Li Q, et al. ZNF503 reduces chemotherapy sensitivity in prostate cancer by activating ISL1 and Notch1 signaling. Cellular Signalling. 2026;145:112602. doi:10.1016/j.cellsig.2026.112602
BibTeX
@article{Nie2026,
author = {Nie, Yong and Fu, Lin and Zeng, Xianyou and Peng, Xingchun and Zhu, Qingguo and Li, Qiuyan and Ye, Liefu},
title = {ZNF503 reduces chemotherapy sensitivity in prostate cancer by activating ISL1 and Notch1 signaling},
journal = {Cellular Signalling},
year = {2026},
volume = {145},
pages = {112602},
doi = {10.1016/j.cellsig.2026.112602}
}
EUVIMED